Insider Buying: KindlyMD (NASDAQ:NAKA) CEO Acquires $179,629.06 in Stock

KindlyMD, Inc. (NASDAQ:NAKA – Get Free Report) CEO David Bailey purchased 32,134 shares of the stock in a transaction on Wednesday, August 19th. The stock was acquired at an average cost of $5.59 per share, for a total transaction of $179,629.06. Following the completion of the acquisition, the chief executive officer owned 32,134 shares of the company’s stock, valued at $179,629.06. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

KindlyMD Trading Up 12.1%

Shares of NASDAQ NAKA traded up $0.76 during trading on Friday, reaching $7.06. 451,586 shares of the company traded hands, compared to its average volume of 199,173. KindlyMD, Inc. has a 12-month low of $3.33 and a 12-month high of $422.40. The stock has a market cap of $126.37 million, a P/E ratio of -0.20 and a beta of 15.95. The firm’s fifty day simple moving average is $4.48 and its 200 day simple moving average is $7.24.

Get KindlyMD alerts:

KindlyMD (NASDAQ:NAKA – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($6.65) earnings per share for the quarter. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 63.45%. The company had revenue of $35.87 million for the quarter. As a group, research analysts expect that KindlyMD, Inc. will post -11.31 EPS for the current year.

Institutional Trading of KindlyMD

A number of institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC grew its holdings in shares of KindlyMD by 76.2% during the second quarter. Geode Capital Management LLC now owns 19,394 shares of the company’s stock worth $484,000 after buying an additional 8,386 shares in the last quarter. Osaic Holdings Inc. purchased a new position in shares of KindlyMD in the second quarter worth about $215,000. Tower Research Capital LLC TRC boosted its position in KindlyMD by 1,638.4% during the third quarter. Tower Research Capital LLC TRC now owns 33,152 shares of the company’s stock worth $827,000 after acquiring an additional 31,245 shares during the last quarter. Victory Capital Management Inc. acquired a new position in KindlyMD during the third quarter worth about $1,007,000. Finally, Vident Advisory LLC purchased a new stake in KindlyMD during the 3rd quarter valued at about $2,092,000.

Analysts Set New Price Targets

Several analysts recently commented on NAKA shares. TD Cowen raised their price target on shares of KindlyMD from $1.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, July 27th. Wall Street Zen upgraded KindlyMD to a “sell” rating in a research report on Saturday, May 23rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of KindlyMD in a research note on Friday, August 7th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $22.33.

Check Out Our Latest Research Report on NAKA

KindlyMD News Summary

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David F. Bailey purchased 4,918 shares at an average price of $5.12, investing approximately $25,180. The transaction raised his direct ownership to 3.18 million shares, which may reassure investors about management’s confidence in KindlyMD’s long-term outlook. CEO stock purchase article
• Neutral Sentiment: Maxim Group improved its EPS forecasts for the fourth quarter of 2026 and the first two quarters of 2027, projecting smaller losses of $0.48, $0.76 and $0.74 per share, respectively. These revisions are modestly encouraging but still indicate that KindlyMD is not expected to reach profitability in the near term. KindlyMD analyst estimates
• Negative Sentiment: Maxim lowered its third-quarter 2026 EPS forecast to a $0.49 loss from a $0.43 loss, cut its fourth-quarter 2027 estimate to a $0.43 loss from a $0.41 loss, and reduced its full-year 2027 forecast to a $2.12 loss from a $1.44 loss. The full-year downgrade points to weaker expected profitability and offsets some of the improved quarterly estimates.
• Negative Sentiment: KindlyMD’s latest reported quarter showed a $6.65-per-share loss on $35.87 million of revenue, alongside a deeply negative net margin. The company is expected to post a loss of approximately $11.31 per share for the current year, while analyst coverage remains mixed, including sell ratings. KindlyMD financial and insider trading data

About KindlyMD

(Get Free Report)

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.

Read More

• Five stocks we like better than KindlyMD
• Blueprint for a Boom: SEC Clears the Crypto Runway
• Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
• Advance Auto Parts Plunged, But Its Turnaround Is Still Working
• Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?

Receive News & Ratings for KindlyMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KindlyMD and related companies with MarketBeat.com's FREE daily email newsletter.